Atelvia Tablet, Delayed Release
Product Images NDC 0430-0979

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Atelvia (NDC 0430-0979). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

The Chemical Structure For Risedronate Is A Pyridinyl Bisphosphonate That Inhibits Osteoclast-mediated Bone Resorption And Modulates Bone Metabolism. Each Atelvia Tablet For Oral Administration Contains The Equivalent Of 35 mg Of Anhydrous Risedronate Sodium In The Form Of The Hemi-pentahydrate With Small Amounts Of Monohydrate. The Empirical Formula For Risedronate Sodium Hemi-pentahydrate Is C7h10no7p2na •2.5 H2o. The Chemical Name Of Risedronate Sodium Is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic Acid] Monosodium Salt. (Atelvia 01)

The Chemical Structure For Risedronate Is A Pyridinyl Bisphosphonate That Inhibits Osteoclast-mediated Bone Resorption And Modulates Bone Metabolism. Each Atelvia Tablet For Oral Administration Contains The Equivalent Of 35 mg Of Anhydrous Risedronate Sodium In The Form Of The Hemi-pentahydrate With Small Amounts Of Monohydrate. The Empirical Formula For Risedronate Sodium Hemi-pentahydrate Is C7h10no7p2na •2.5 H2o. The Chemical Name Of Risedronate Sodium Is [1-hydroxy-2-(3-pyridinyl)ethylidene]bis[phosphonic Acid] Monosodium Salt. (Atelvia 01)
FDA Label Image

Figure 1 (Atelvia 02)

Figure 1 (Atelvia 02)
The text appears to be a caption for Figure 1. The figure likely shows the cumulative incidence of nonvertebral osteoporosis-related fractures over a 3-year period, comparing the placebo group to those taking either ACTONEL 5mg or a combination of VERT MN and VERT NA. The notation "[]" may indicate some additional information, but without further context, its meaning is not clear.*
FDA Label Image

Principal Display Panelndc 0430-0979-03atelvia 35 mg(risedronate Sodium) Delayed-release Tabletsonce-a-week4 Tabletsrx Only (Atelvia 03)

Principal Display Panelndc 0430-0979-03atelvia 35 mg(risedronate Sodium) Delayed-release Tabletsonce-a-week4 Tabletsrx Only (Atelvia 03)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.